Informa Life Sciences will be holding its 25th Annual EU Pharmaceutical Law Forum on May 24-26, 2016 in Brussels, Belgium. The conference will offer presentations on the following topics:
• Feedback from the EU Commission on competition law (keynote presentation);
• Reverse payment patent settlements;
• Discounts, rebates and excessive pricing in the pharmaceutical industry;
• Key issues and pitfalls in the merger control review of pharmaceuticals transactions;
• Understanding the latest developments in SPCs;
• Enforcing second medical use patents;
• Lifecycle management with respect to competition law, patents and regulatory frameworks;
• Current state of the art and work in progress at the European Medicines Agency;
• Form follows function? Implementation of EU regulatory frameworks in pharmaceutical law at the EU Commission (keynote presentation);
• Marketing, advertising, social media, mobile aps and e-health;
• Orphan Regulation: 15 years later -- Ready for the future?
• Transparency of clinical trial data, other regulatory data and prices;
• Biosimilars and the regulatory frameworks;
• Adaptive licensing and early access to medicines;
• Quiz time! Competition law, patents, regulatory frameworks and pot luck;
• Revisions to the medical devices regulation and the IVD regulation;
• Impact of the new data privacy regulation;
• Examining the new safe harbour ruling/agreement;
• Data privacy and clinical trial data;
• Transparency with regards to payments to healthcare professionals;
• Essential guidance on the use of mobile apps and e-health with respect to privacy;
• Accountability and record keeping in a pharma context -- An imperative requirement of the GDPR;
• Anti-bribery and enforcement trends across the EU and Deferred Prosecution Agreements (DPAs): Private practice perspective;
• Anti-bribery from a practical in-house counsel perspective;
• Ensuring efficient internal investigations;
• How to mitigate risk;
• Examining commercial intellectual property issues in collaboration and licensing agreements;
• The importance of due diligence;
• Obligations to exploit;
• Assessing the financial aspects of licensing and collaboration agreements;
• Legal and BD&L perspective: The importance of alliance management in licensing deals;
• Planning, negotiating and drafting termination provisions;
• Co-marketing/co-promotion agreements in the pharma industry);
• Outlining a recent asset deal in the pharmaceutical industry; and
• Industry case study.
An agenda for this conference, including detailed descriptions of conference sessions and list of speakers, can be found here. Registration fee packages for the forum can be found here. Those interested in registering for the conference can do so here.
Patent Docs is a media partner of the EU Pharmaceutical Law Forum.
Comments